Search results
Vaccine stocks gain, Moderna and Pfizer in talks with the US on bird flu vaccines By Investing.com
Investing.com· 1 day agoVaccine stocks gain, Moderna and Pfizer in talks with the US on bird flu vaccines
Pfizer rolls out another cost-cutting program, sets $1.5 billion target by 2027
Reuters via Yahoo Finance· 2 days agoInvestors have fled from Pfizer as pandemic worries declined and billions of dollars in COVID-19 ...
Moderna and Pfizer In Talks With U.S. To Make a Bird Flu Vaccine
Barrons.com· 2 days ago“We continue to have active conversations with both manufacturers, and the negotiations are...
Pfizer Initiates Multi-Year Cost Reduction Plan Targeting $1.5B Savings By 2027 - Pfizer (NYSE:PFE)
Benzinga· 1 day agoWhat Happened: The new program builds on a $4 billion cost reduction plan announced last year,...
Pfizer plans to cut costs by $1.5 billion as demand for COVID vaccine dwindles
Quartz· 2 days agoPharma giant Pfizer announced Wednesday another cost-cutting initiative as the company struggles...
Chinese CDMO takes over Pfizer’s UK facility; Serum Institute ships malaria vaccine to Africa
Endpoints News· 1 day agoAsymchem Laboratories will take over operations at Pfizer’s API facility in Sandwich, UK, which the pharma company previously said it would downsize. The facility is Asymchem ...
Pfizer (NYSE:PFE) Shares Up 2%
ETF DAILY NEWS· 7 hours agoPfizer Inc. (NYSE:PFE – Get Free Report)’s share price was up 2% during trading on Wednesday . The stock traded as high as $29.18 and last traded at $29.13 ...
Why Vaccine Stocks Rallied This Week
Motley Fool via Yahoo Finance· 5 hours agoUnlike the COVID-19 pandemic, when the U.S. government subsidized private companies to make the COVID...
Moderna wins a battle in vaccine patent dispute with Pfizer-BioNTech - The Boston Globe
The Boston Globe· 7 days agoModerna said Friday that the European Patent Office has upheld the validity of one of its key...
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
Zacks via Yahoo Finance· 1 day agoThis is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first...
